NCT07137871View on ClinicalTrials.gov

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Breast Cancer Metastatic
Interventions
DRUG

Avasopasem

Avasopasem has also been shown to exhibit both antitumor effects as well as minimal toxicity. Participants are currently taking a CDK 4/6 inhibitor and hormonal therapy

Trial Locations (1)

78229

Mays Cancer Center, UT Health San Antonio, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER